Undeniably, immunotherapy has revolutionized the treatment of hematologic malignancies. Specially, NK/CIK/CAR-T cell therapies have shown tremendous success in the treatment of these clinically challenging malignancies. Certainly, the efforts to integrate immune checkpoint blockades, novel inhibitors, and other immune/cancer cell therapies have contributed significantly to the unprecedented success of these aforementioned therapies across basic and translational immunotherapy research. However, a subset of patients continue to be unresponsive, thus emphasizing the need to further improve the therapeutic paradigm.
Considering this, we greatly welcome contributions that address existing and novel strategies to advance NK/CIK/CAR-T immunotherapies in the preclinical and clinical settings of hematologic malignancies. Particular attention will be given to hypothesis-driven studies with strong preliminary data and novel ideas to improve/enhance the long lasting effects of these therapies.
This special issue aims to publish research articles, reviews and perspectives that address clinical/translational cancer immunotherapy, with an emphasis on NK/CIK/CAR-T. Computational approaches with experimental validations, in vitro and in vivo studies related to new immunotherapeutic approaches, epigenetic insights ,and biomarkers are of interest.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Undeniably, immunotherapy has revolutionized the treatment of hematologic malignancies. Specially, NK/CIK/CAR-T cell therapies have shown tremendous success in the treatment of these clinically challenging malignancies. Certainly, the efforts to integrate immune checkpoint blockades, novel inhibitors, and other immune/cancer cell therapies have contributed significantly to the unprecedented success of these aforementioned therapies across basic and translational immunotherapy research. However, a subset of patients continue to be unresponsive, thus emphasizing the need to further improve the therapeutic paradigm.
Considering this, we greatly welcome contributions that address existing and novel strategies to advance NK/CIK/CAR-T immunotherapies in the preclinical and clinical settings of hematologic malignancies. Particular attention will be given to hypothesis-driven studies with strong preliminary data and novel ideas to improve/enhance the long lasting effects of these therapies.
This special issue aims to publish research articles, reviews and perspectives that address clinical/translational cancer immunotherapy, with an emphasis on NK/CIK/CAR-T. Computational approaches with experimental validations, in vitro and in vivo studies related to new immunotherapeutic approaches, epigenetic insights ,and biomarkers are of interest.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
